[1].Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J].Lancet, 2020, 395(10225):709-733
[2]Hickson LJ, Negrotto SM, Onuigbo M, et al.Echocardiography Criteria for Structural Heart Disease in Patients With End-Stage Renal Disease Initiating Hemodialysis[J].J Am Coll Cardiol, 2016, 67(10):1173-1182
[3]Budoff MJ, Rader DJ, Reilly MP, et al.Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study[J].Am J Kidney Dis, 2011, 58(4):519-526
[4]Hedayati SS.A Novel Treatment for Vascular Calcification in Patients With Dialysis-Dependent Chronic Kidney Disease: Are We There Yet?[J].Circulation, 2020, 141(9):740-742
[5]Himmelsbach A, Ciliox C, Goettsch C.Cardiovascular Calcification in Chronic Kidney Disease-Therapeutic Opportunities[J].Toxins, 2020, 12(3):181-
[6]Hashiba H, Aizawa S, Tamur K, et al.Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects[J].Ther Apher Dial, 2006, 10(1):59-64
[7]Price PA, Roublick AM, Williamson MK.Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate[J].Kidney Int, 2006, 70(9):1577-1183
[8]Torregrosa JV, Durán CE, Barros X, et al.Successful treatment of calcific uraemic arteriolopathy with bisphosphonates[J].Nefrologia, 2012, 32(3):329-334
[9].KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)[J].Kidney Int Suppl (2011), 2017, 7(1):1-59
[10]王莉, 李贵森, 刘志红.中华医学会肾脏病学分会《慢性肾脏病矿物质和骨异常诊治指导[J].肾脏病与透析肾移植杂志, 2013, 22(6):554-559
[11]Persy V, De Broe M, Ketteler M.Bisphosphonates prevent experimental vascular calcification: Treat the bone to cure the vessels?[J].Kidney Int, 2006, 70(9):1537-1538
[12]García-Gómez MC, Vilahur G.Osteoporosis and vascular calcification: A shared scenario[J].Clin Investig Arterioscler, 2020, 32(1):33-42
[13]Nitta K, Akiba T, Suzuki K, et al.Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis[J].Am J Kidney Dis, 2004, 44(4):680-688
[14]Torregrosa JV, Sánchez-Escuredo A, Barros X, et al.Clinical management of calcific uremic arteriolopathy before and after therapeutic inclusion of bisphosphonates[J].Clin Nephrol, 2015, 83(4):231-234
[15]Moher D, Liberati A, Tetzlaff J, et al.Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.[J].PLoS Med, 2009, 6(7):e1000097-
[16]Higgins JPT, Altman DG, G?tzsche PC, et al.The Cochrane Collaboration' s tool for assessing risk of bias in randomised trials[J].BMJ, 2011, 343:d5928-
[17]Ariyoshi T, Eishi K, Sakamoto I, et al.Effect of etidronic acid on arterial calcification in dialysis patients[J].Clin Drug Investig, 2006, 26(4):215-222
[18]Hashiba H, Aizawa S, Tamura K, et al.Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients[J].Ther Apher Dial, 2004, 8(3):241-247
[19]Okamoto M, Yamanaka S, Yoshimoto W, et al.Alendronate as an effective treatment for bone loss and vascular calcification in kidney transplant recipients[J].J Transplant, 2014, 2014:269613-
[20]Torregrosa JV, Fuster D, Gentil MA, et al.Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients[J].Transplantation, 2010, 89(12):1476-1481
[21] Toussaint ND, Lau KK, Strauss BJ, et al.Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial[J].Am J Kidney Dis, 2010, 56(1):57-68
[22]Torregrosa JV, Fuster D, Gentil MA, et al.Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients[J].Transplantation, 2010, 89(12):1476-1481
[23]Moe SM, Chen NX.Mechanisms of vascular calcification in chronic kidney disease[J].J Am Soc Nephrol, 2008, 19(2):213-216
[24]Villa-Bellosta R, Egido J.Phosphate,pyrophosphate,and vascular calcification: a question of balance[J].Eur Heart J, 2017, 38(23):1801-1804
[25]Francis MD, Russell RG, Fleisch H.Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo[J].Science, 1969, 3899:1264-1266
[26]Nigwekar SU, Thadhani R, Brandenburg VM.Calciphylaxis[J].N Engl J Med, 2018, 378(18):1704-14
[27]Monney P, Nguyen QV, Perroud H, et al.Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure[J].Nephrol Dial Transplant, 2004, 19(8):2130-2132
[28]Musso CG, Enz PA, Guelman R, et al.Non-ulcerating calcific uremic arteriolopathy skin lesion treated successfully with intravenous ibandronate[J].Perit Dial Int, 2006, 26(6):717-718
[29]Shiraishi N, Kitamura K, Miyoshi T, et al.Successful treatment of a patient with severe calcific uremic arteriolopathy (calciphylaxis) by etidronate disodium[J].Am J Kidney Dis, 2006, 48(1):151-154
[30]Truong DH, Riedhammer MM, Zinszer K.Non-uraemic calciphylaxis successfully treated with pamidronate infusion[J].Int Wound J, 2019, 16(1):250-255
[31]Caffarelli C, Montagnani A, Nuti R, et al.Bisphosphonates, atherosclerosis and vascular calcification: update and systematic review of clinical studies[J].Clin Interv Aging, 2017, 12:1819-1828
[32]Santos LL, Cavalcanti TB, Bandeira FA.Vascular effects of bisphosphonates-a systematic review[J].Clin Med Insights Endocrinol Diabetes, 2012, 5:47-54
[33]Kranenburg G, Bartstra JW, Weijmans M, et al.Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis[J].Atherosclerosis, 2016, 252:106-115
[34]Ylitalo R.Bisphosphonates and atherosclerosis[J].Gen Pharmacol, 2000, 35(6):287-296
[35]Ylitalo R, Kalliovalkama J, Wu X, et al.Accumulation of bisphosphonates in human artery and their effects on human and rat arterial function in vitro[J].Pharmacol Toxicol, 1998, 83(3):125-131
[36]Patntirapong S, Poolgesorn M.Alteration of macrophage viability, differentiation, and function by bisphosphonates[J].Oral Dis, 2018, 24(7):1294-1302
[37]Wang L, Guo TZ, Hou S, et al.Bisphosphonates Inhibit Pain, Bone Loss, and Inflammation in a Rat Tibia Fracture Model of Complex Regional Pain Syndrome[J].Anesth Analg, 2016, 123(4):1033-1045
